Cargando…

Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft

Nimotuzumab is a humanized anti-epidermal growth factor receptor I (EGFR) monoclonal antibody. We have developed antibody drug conjugates (ADCs) with nimotuzumab conjugated to PEGylated-maytansine (PEG(6)-DM1). We generated conjugates with low (nimotuzumab-PEG(6)-DM1-Low: DAR = 3.5) and high (nimotu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hartimath, Siddesh V., El-Sayed, Ayman, Makhlouf, Amal, Bernhard, Wendy, Gonzalez, Carolina, Hill, Wayne, Parada, Angel Casaco, Barreto, Kris, Geyer, Clarence Ronald, Fonge, Humphrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383682/ https://www.ncbi.nlm.nih.gov/pubmed/30800216 http://dx.doi.org/10.18632/oncotarget.26613

Ejemplares similares

Near infrared fluorescence imaging of EGFR expression in vivo using IRDye800CW-nimotuzumab
por: Bernhard, Wendy, et al.
Publicado: (2017)

Evaluation of nimotuzumab Fab(2) as an optical imaging agent in EGFR positive cancers
por: Bernhard, Wendy, et al.
Publicado: (2023)

Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety
por: Bernhard, Wendy, et al.
Publicado: (2021)

Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF-1R) positive cancer
por: Solomon, Viswas Raja, et al.
Publicado: (2020)

(89)Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I
por: Chekol, Rufael, et al.
Publicado: (2018)

Near infrared imaging of epidermal growth factor receptor positive xenografts in mice with domain I/II specific antibody fragments
por: Bernhard, Wendy, et al.
Publicado: (2019)

Evaluation of antibody fragment properties for near-infrared fluorescence imaging of HER3-positive cancer xenografts
por: El-Sayed, Ayman, et al.
Publicado: (2018)

(89)Zr-Labeled Domain II-Specific scFv-Fc ImmunoPET Probe for Imaging Epidermal Growth Factor Receptor In Vivo
por: Alizadeh, Elahe, et al.
Publicado: (2021)

Nimotuzumab Site-Specifically Labeled with (89)Zr and (225)Ac Using SpyTag/SpyCatcher for PET Imaging and Alpha Particle Radioimmunotherapy of Epidermal Growth Factor Receptor Positive Cancers
por: Solomon, Viswas Raja, et al.
Publicado: (2020)

Production and Semi-Automated Processing of (89)Zr Using a Commercially Available TRASIS MiniAiO Module
por: Gaja, Vijay, et al.
Publicado: (2020)

Imaging Immune Cells Using Fc Domain Probes in Mouse Cancer Xenograft Models
por: Bernhard, Wendy, et al.
Publicado: (2022)

A novel synthetic trivalent single chain variable fragment (tri-scFv) construction platform based on the SpyTag/SpyCatcher protein ligase system
por: Alam, Md. Kausar, et al.
Publicado: (2018)

First Ring‐Expanded Maytansin Lactone Accessed by a New Mutasynthetic Variant
por: Wesemann, Friederike, et al.
Publicado: (2020)

Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma
por: Liang, Renba, et al.
Publicado: (2021)

A fluorescence anisotropy assay to discover and characterize ligands targeting the maytansine site of tubulin
por: Menchon, Grégory, et al.
Publicado: (2018)

Optimization of the Imaged cIEF Method for Monitoring the Charge Heterogeneity of Antibody-Maytansine Conjugate
por: Abbood, Ayat
Publicado: (2023)

EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects
por: Perez, Rolando, et al.
Publicado: (2011)

Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment
por: Londres, Henrry Diaz, et al.
Publicado: (2022)

An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC
por: Huang, Yanping, et al.
Publicado: (2023)

Biodistribution and Tumor Uptake of (67)Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft
por: Izquierdo-Sánchez, Vanessa, et al.
Publicado: (2018)

Next-generation sequencing-guided identification and reconstruction of antibody CDR combinations from phage selection outputs
por: Barreto, Kris, et al.
Publicado: (2019)

Zein nanoparticles as nontoxic delivery system for maytansine in the treatment of non-small cell lung cancer
por: Yu, Xianglong, et al.
Publicado: (2019)

Heterogeneity of resistant mechanisms in an EGFR-TKI relapsed patient with EGFR amplification and response to nimotuzumab: A case report
por: Li, Yan, et al.
Publicado: (2022)

Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab
por: Garrido, Greta, et al.
Publicado: (2017)

Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2018)

MicroRNA-566 activates EGFR signaling and its inhibition sensitizes glioblastoma cells to nimotuzumab
por: Zhang, Kai-Liang, et al.
Publicado: (2014)

Nimotuzumab enhances temozolomide‐induced growth suppression of glioma cells expressing mutant EGFR in vivo
por: Nitta, Yusuke, et al.
Publicado: (2016)

A (89)Zr-labeled lipoplex nanosystem for image-guided gene delivery: design, evaluation of stability and in vivo behavior
por: Hajdu, Istvan, et al.
Publicado: (2018)

Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3
por: Zhao, Lei, et al.
Publicado: (2012)

Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells
por: Bauzon, Maxine, et al.
Publicado: (2019)

Nimotuzumab for COVID-19: case series
por: Abdo Cuza, Anselmo A, et al.
Publicado: (2021)

Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status
por: Chong, Dawn Q, et al.
Publicado: (2015)

Development of an Epidermal Growth Factor Derivative with EGFR Blocking Activity
por: Panosa, Clara, et al.
Publicado: (2013)

Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study
por: She, Lei, et al.
Publicado: (2022)

Profile of nimotuzumab in the treatment of high-grade glioma
por: Yang, Qun-ying, et al.
Publicado: (2015)

Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck
por: Crombet Ramos, Tania, et al.
Publicado: (2020)

Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts
por: Lam, Sze-Kwan, et al.
Publicado: (2017)

Nimotuzumab abrogates acquired radioresistance of KYSE-150R esophageal cancer cells by inhibiting EGFR signaling and cellular DNA repair
por: Liu, Hai, et al.
Publicado: (2015)

Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin
por: González Fernández, Sandra, et al.
Publicado: (2022)

Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients
por: Mazorra, Zaima, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nm2st2rips2rjf0jjvimfv2mvt